Alluvi Wolverine Stack (BPC-157 & TB-500) 40mg

Description

Alluvi Wolverine Stack is a research-grade dual-peptide formulation combining BPC-157 (20mg) and TB-500 (20mg) in a single 40mg pre-filled pen. Independently verified content: 21.99mg BPC-157 and 19.59mg TB-500 per pen, at 99.5% analytical purity (Janoshik Analytical, batch BP1701FSR).

In preclinical and cellular literature, these compounds are investigated for their complementary actions on vascular signalling and cytoskeletal cellular motility.

Why These Two Peptides Are Studied Together

BPC-157 — Vascular Signalling and Connective Tissue Biology

Body Protection Compound-157 is a 15-amino acid sequence initially derived from human gastric juice proteins. In experimental models, BPC-157 is studied for its interactions with tissue-response pathways. Published preclinical studies report that BPC-157 interacts with vascular endothelial growth factor (VEGF) pathways, stimulating angiogenesis — the formation of new micro-capillary networks. Researchers examine this mechanism in tendon-to-bone healing models, ligament tear preparations, and soft tissue damage, evaluating how increased micro-vascularisation influences fibroblast outgrowth and collagen structural organisation.

TB-500 — Cytoskeletal Actin Regulation and Cellular Migration

TB-500 is a synthetic fraction of Thymosin Beta-4, an endogenous 43-amino acid protein found in high concentrations in platelets and wound fluid. TB-500’s primary mechanism in cellular literature is actin regulation. By binding to and sequestering monomeric G-actin, TB-500 facilitates cellular migration. In tissue culture models, this allows endothelial cells and dermal fibroblasts to migrate rapidly toward sites of mechanical stress and tissue damage.

Investigated Synergistic Interactions

Combining BPC-157 and TB-500 introduces two distinct biological pathways within one experimental matrix. While BPC-157 is studied for promoting new blood vessel networks, TB-500 is investigated for mobilising the structural cells that travel through those vessels. Laboratory models examine whether concurrent presence produces additive tissue-remodelling responses.

Note: These mechanisms represent biological observations from published in-vitro and animal literature. They do not constitute therapeutic outcomes, and this material is not supplied for human administration.

Product Specifications

Storage and Handling

Multi-peptide preparations require careful laboratory handling to maintain molecular stability and prevent chain shearing.

• Refrigerate at 2°C to 8°C immediately on receipt. Protect from direct light. Never freeze pre-filled liquid pens — ice crystal formation permanently degrades fragile peptide chains.
• No reconstitution required. Unlike conventional lyophilised peptide vials requiring manual dilution with bacteriostatic water, the Alluvi Wolverine Stack is factory-formulated in a sterile liquid buffer — eliminating concentration discrepancies and needle damage.
• Check on arrival: confirm outer packaging, holographic tamper seal, and UV security watermark are intact. Verify batch reference BP1701FSR against the certificate. Refrigerate immediately. Report transit damage or suspected temperature excursions within 48 hours.
• Batch consistency and precision. In multi-peptide research, precise ratio maintenance between BPC-157 and TB-500 is critical. Batch-specific HPLC documentation ensures each component is quantified independently.
• Purity is not sterility. An analytical purity score of 99.5% confirms the presence of the intended peptides and absence of truncated fragments. It does not certify sterility for human consumption or clinical administration.

The Alluvi Healthcare Standard

• Independent Third-Party Analysis. HPLC and mass spectrometry completed per batch by Janoshik Analytical. Public task numbers checkable directly on the lab database.
• Individual Peptide Assay Quantification. The laboratory certificate verifies independent milligram content for both BPC-157 (21.99mg) and TB-500 (19.59mg), confirming a consistent active ratio.
• Cold-Chain Transport. Dispatched in insulated packaging with thermal ice packs to protect peptide stability throughout transit.
• Lot Traceability. Outer boxes and pen cartridges carry identical batch identifiers linked directly to published laboratory certificates.
• Sealed Multi-Dose Device. Pre-calibrated liquid format prevents contamination risks and eliminates user reconstitution errors.

Important Research Disclaimer

Strictly for Laboratory and Scientific Research Use Only.

Alluvi Wolverine Stack is not intended for human consumption, veterinary use, self-administration, clinical use, treatment, diagnosis, prevention, or any form of personal use. It is not approved by the MHRA, EMA, or FDA for human or veterinary use.

We do not provide dosing guidance, preparation instructions, administration guidance, or personal-use support. Customers must ensure all products are handled responsibly within appropriate laboratory and scientific research environments.